Quest Diagnostics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $585 Mil. Quest Diagnostics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $4,913 Mil. Quest Diagnostics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $6,307 Mil.
Quest Diagnostics's debt to equity for the quarter that ended in Dec. 2023 was 0.87.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Quest Diagnostics's Debt-to-Equity or its related term are showing as below:
DGX'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.71 Med: 0.79 Max: 0.96
Current: 0.87
During the past 13 years, the highest Debt-to-Equity Ratio of Quest Diagnostics was 0.96. The lowest was 0.71. And the median was 0.79.
Quest Diagnostics Debt-to-Equity Historical Data
The historical data trend for Quest Diagnostics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Quest Diagnostics Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
Get a 7-Day Free Trial
|
|
|
0.96 |
0.71 |
0.74 |
0.80 |
0.87 |
|
Quest Diagnostics Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
0.80 |
0.76 |
0.79 |
0.77 |
0.87 |
Competitive Comparison
For the Diagnostics & Research subindustry, Quest Diagnostics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quest Diagnostics Debt-to-Equity Distribution
For the Medical Diagnostics & Research industry and Healthcare sector, Quest Diagnostics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Quest Diagnostics's Debt-to-Equity falls into.
Quest Diagnostics Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Quest Diagnostics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Quest Diagnostics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quest Diagnostics (Quest Diagnostics) Business Description
Traded in Other Exchanges
Address
500 Plaza Drive, Secaucus, NJ, USA, 07094
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Executives
| Luis Diaz |
director |
C/O JOUNCE THERAPEUTICS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02138 |
| Michael E Prevoznik |
officer: Corp VP, Legal & Compliance |
C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
| Catherine T. Doherty |
officer: SVP, Physician Services Bus. |
C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
| Timothy M Ring |
director |
C/O C.R BARD INC, 730 CENTRAL AVE, MURRAY HILL NJ 07974 |
| Mark E Delaney |
officer: SVP & Chief Commercial Officer |
500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094 |
| Mark A Gardner |
officer: SVP of Molecular Gen & Oncol |
500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094 |
| Patrick Plewman |
officer: SVP for Diagnostic Services |
500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094 |
| Karthik Kuppusamy |
officer: SVP, Clinical Solutions |
500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094 |
| Michael J Deppe |
officer: VP, Corp. Controller & CAO |
500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS, SECAUCUS NJ 07094 |
| Samer Abdul Samad |
officer: Executive Vice President & CFO |
5200 ILLUMINA WAY, SAN DIEGO CA 92122 |
| Stephen H Rusckowski |
director, officer: President and CEO |
C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
| Tracey Doi |
director |
C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
| Gail R Wilensky |
director |
C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
| Mark Guinan |
officer: Senior Vice President & CFO |
C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
| Daniel Stanzione |
director |
C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
Quest Diagnostics (Quest Diagnostics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DGX has been successfully added to your